Senior Director CDTL - Immunology

At Johnson & Johnson,we believe health is everything.

Our strength in healthcare innovation empowers us to build aworld where complex diseases are prevented, treated, and cured,where treatments are smarter and less invasive, andsolutions are personal.Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.Learn more at jnj.com

As guided by Our Credo, Johnson & Johnson is responsible to our employees who work with us throughout the world.

We provide an inclusive work environment where each person is considered as an individual.

At Johnson & Johnson, we respect the diversity and dignity of our employees and recognize their merit.

Job Function:
Discovery & Pre-Clinical/Clinical Development

Job Sub Function:
Clinical Development & Research - Non-MD

Job Category:
Scientific/Technology

All Job Posting Locations:
Spring House, Pennsylvania, United States of America

Job Description:

The Compound Development Team Leader (CDTL) may work across disease areas (Rheumatology, Gastroenterology, and Immunodermatology) focused on the early portfolio assets.

The CDTL will partner closely with the Portfolio & Asset Management organization as part of the wider CDTL community.

They will lead a cross-functional compound development team to maximize the value of the asset and drives execution of the compound strategy.

The CDTL champions the project(s) at all levels of J&J through providing clear communication, creative strategic approaches to development and securing appropriate resources to deliver on the milestones.

The CDTL leads a cross-functional matrix compound development team to deliver against the asset strategy.

Beginning at Lead Optimization entry the CDTL drives the development and execution of the compound strategy, working in close partnership with the Discovery Project Leader.

The CDTL becomes the sole project team leader at New Molecular Entity Designation and is accountable for Phase 1-3 trials related to the compound development program.

Responsibilities include but are not limited to:

• Lead the development and execution of the compound development strategy across multiple indications and/or for multiple programs, creating a vision for each compound within the TA portfolio, including identifying potential indication to be pursued and sequencing of these indications.

• Assembles and leads an early CDT with representation from appropriate functional partners, for the creation of a Development Plan that provides a thorough and clear asset strategy, integrating input from all functional areas, identifying key development issues and the strategic approach to each, with associated timelines and budgets, offering clarity on alternative pathways and tradeoffs considered.

o Creates the target product profile in collaboration with commercial, market access and clin...